GSK-2434735

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameGSK-2434735

Drug Alias Nameanti-IL-4/IL-13 human dAbdual-targeting dAb therapyGSK-2434735

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionInterleukin-13 inhibitorsInterleukin-4 inhibitors

TargetsInterleukin-4Interleukin-13

Therapy Area/IndicationsAsthma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlaxosmithkline Plc

Active IndicationsN/A

Inactive IndicationsAsthma

Other Information

ATC CodeN/A